Showing results (31-40 of 45) with videos related to
Sort By:
Pageof 5
Breast Cancer Research : BCR|May 21, 2020
ERα-36 regulates progesterone receptor activity in breast cancerHenri-Philippe Konan, Loay Kassem, Soleilmane Omarjee, et al.BMC Cancer|June 5, 2015
TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patientsLoay Kassem, Mathieu Deygas, Laurent Fattet, et al.Journal of Hepatocellular Carcinoma|December 5, 2018
Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)Hamdy A Azim, Ashraf Omar, Hesham Atef, et al.Cancer Research|January 14, 2018
Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10Adrien Nougarede, Nikolay Popgeorgiev, Loay Kassem, et al.Breast Cancer Research and Treatment|September 25, 2021
Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypesRomain Teinturier, Razan Abou Ziki, Loay Kassem, et al.Cardiovascular Toxicology|July 8, 2025
Safety of Permissive Cardiotoxicity of Trastuzumab in Patients with Breast Cancer: A Systematic Review and Meta-AnalysisAmira Mohamed Taha, Ramez M Odat, Wesam Abd El-Tawab Moawad, et al.EMBO Molecular Medicine|July 17, 2023
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancerCoralie Poulard, Thuy Ha Pham, Youenn Drouet, et al.Oncology and Therapy|September 21, 2023
The Landscape of BRCA Mutations among Egyptian Women with Breast CancerHamdy A Azim, Samah A Loutfy, Hatem A Azim, et al.Journal of the Egyptian National Cancer Institute|December 14, 2021
Pathological responses and survival outcomes in patients with locally advanced breast cancer after neoadjuvant chemotherapy: a single-institute experienceKyrillus S Shohdy, Doaa S Almeldin, Madonna A Fekry, et al.Breast Cancer Research : BCR|May 22, 2021
Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrantJulien Jacquemetton, Loay Kassem, Coralie Poulard, et al.Pageof 5